azasetron has been researched along with Lung Neoplasms in 2 studies
azasetron: a selective 5-HT3 receptor antagonist; structure given in first source;
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral azasetron was found to be non-inferior to intravenous granisetron in the acute antiemetic effect against moderately emetogenic chemotherapy." | 2.77 | A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy. ( Endo, J; Funaguchi, N; Iihara, H; Ito, F; Itoh, Y; Kamiya, F; Minatoguchi, S; Ohno, Y; Yamada, M; Yanase, K, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, J | 1 |
| Iihara, H | 1 |
| Yamada, M | 1 |
| Yanase, K | 1 |
| Kamiya, F | 1 |
| Ito, F | 1 |
| Funaguchi, N | 1 |
| Ohno, Y | 1 |
| Minatoguchi, S | 1 |
| Itoh, Y | 1 |
| Hayakawa, T | 1 |
| Sato, M | 1 |
| Konaka, M | 1 |
| Makino, A | 1 |
| Hirohata, T | 1 |
| Totsu, S | 1 |
| Wada, Y | 1 |
| Sato, H | 1 |
| Inotsume, N | 1 |
| Fujita, A | 1 |
| Sekine, K | 1 |
1 trial available for azasetron and Lung Neoplasms
| Article | Year |
|---|---|
A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemother | 2012 |
1 other study available for azasetron and Lung Neoplasms
| Article | Year |
|---|---|
[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bi | 2006 |